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(100.3 and 99.6, respectively). ConClusions: Comorbidities, BMI, disease severity, 
and hospitalizations rates were stable over 3 years of follow-up for schizophrenia 
patients, an important finding for burden of schizophrenia disease assessment.
PMH7
CoMParing tHe influenCe of MontH of birtH and gender in two 
aCadeMiC years on attention defiCit HyPeraCtivity disorder 
diagnoses (adHd) aMong CHildren in tHe HealtH iMProveMent 
network (tHin) uk data
O’Leary C, Bourke A., Ansell D.
CSD Medical Research UK, London, UK
objeCtives: Long-term costs follow a diagnosis of ADHD; therefore it is important 
to examine factors influencing diagnosis. This study determines the prevalence of 
ADHD among children according to month of birth and gender across two academic 
years. Methods: Children aged 5-15 years in the academic years Sep 2010-Aug 
2011 (Year 1) and Sep 2011-Aug 2012 (Year 2) in The Health Improvement Network 
(THIN) were assessed for ADHD using diagnoses and prescriptions. Percentages were 
calculated and differences across month of birth assessed using chi squared tests 
for trend. Children with later months of birth (Mar-Aug) were compared to earlier 
months of birth (Sep-Feb), and males to females using relative risks (RR). Results: 
436,299 children in Year 1 and 398,718 in Year 2 were included with 0.75% and 0.76% 
diagnosed with ADHD respectively. There was evidence at the 5% level of an increas-
ing trend in ADHD prevalence in both academic years (p< 0.001, p= 0.005 in Year 
1, Year 2 respectively). Younger children were 14% more likely (RR= 1.14, 95% CI 
1.07-1.23) in Year 1 and 12% more likely (RR= 1.12 95% CI 1.04-1.20) in Year 2 to have 
ADHD than older children. Males were around five times more likely to have an 
ADHD diagnosis in both years (RR= 5.00 95% CI 4.56-5.49, RR= 4.92 95% CI 4.47-5.42 
in Year 1, Year 2 respectively). ConClusions: There was good agreement across 
academic years both in the percentage with ADHD diagnosis, and the increasing 
trend through the academic year. Younger children were more likely to be diagnosed 
with ADHD than their older peers. This may partly be due to them appearing to lack 
the maturity of their older classmates. Males were more likely to have an ADHD 
diagnosis than females in both years. Further work could assess the differences in 
different age groups and be extended to include other conditions.
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objeCtives: According to 2013 American Geriatrics Society Updated Beers Criteria, 
paroxetine has strong anticholinergic properties than other Selective Serotonin 
Reuptake Inhibitors (SSRIs). Such anticholinergic effects may lead to adverse cog-
nitive outcomes. This study examined the risk of dementia associated with the 
use of paroxetine versus other SSRIs. Methods: A retrospective cohort study 
was conducted using 2007-2010 Medicare claims data, and included nursing home 
residents > 65 years with depression. The study focused on incident SSRI users 
who did not have dementia in 2007 (baseline). Patients were included if they had 
continuous coverage for Medicare Parts A, B and D and no HMO coverage during 
the one year baseline and 2 years of follow up or until death. The primary outcome 
of this study was time to dementia diagnosis. SSRIs were classified as paroxetine 
and others. Cox proportional hazards regression was conducted to evaluate the risk 
of dementia with the use of paroxetine versus other SSRIs. Results: The study 
cohort consisted of 19,050 elderly nursing home residents with depression. Among 
SSRI users, 1,716 (9.01%) received paroxetine and 17,334 (90.99%) received others. 
Since proportional-hazard assumption was violated, the extended Cox hazard 
model involving Heaviside function was used to evaluate the dementia risk. The 
extended model revealed that paroxetine users had 66% [Hazards Ratio, HR, 1.66; 
95% Confidence Interval (CI), 1.03-2.67] higher risk for dementia than other SSRIs 
users after 390 days of treatment. However, the dementia risk did not vary within 
390 days of SSRI use. Other factors positively associated with dementia risk were age, 
male gender, and non-White race. ConClusions: Paroxetine use was associated 
with a time-varying increase in risk of dementia among depressed elderly nursing 
home residents. There is a need to optimize anticholinergic medication use in this 
population as depression is an independent risk factor for dementia.
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objeCtives: Bipolar depression is characterized by depressive symptoms and 
impairment in many areas of functioning, including work, family, and social life. 
There is continuing need for treatment options that provide remission in symp-
toms and functioning. The efficacy of lurasidone on symptom remission of bipo-
lar depression has been demonstrated previously. The objective of this study was 
to assess the effect of lurasidone on functional remission. Methods: Post-hoc 
analysis of a 6-week, randomized, double-blind, placebo-controlled clinical trial of 
lurasidone (20–60 mg or 80-120 mg) versus placebo was conducted. Functioning was 
measured using the Sheehan Disability Scale (SDS), a validated patient-reported 
outcome measure assessing functioning in terms of work/school, family, and social 
life (higher scores indicate lower functioning). Functional remission (defined as 
SDS total score ≤ 6) was compared between lurasidone and placebo groups using 
logistic regressions. Results: In this 6-week trial (N= 485), few participants were 
in functional remission at baseline (1.7%). The mean change in SDS total score from 
baseline to study endpoint was -10.4 (SD = 7.49) in the lurasidone group and -7.1 
(SD = 8.27) in the placebo group. A greater percentage of participants on lurasidone 
achieved functional remission in comparison to placebo (40.9% vs. 25.5%, p= 0.01) 
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objeCtives: Despite the growing use of antidepressants (AD) and the potential 
grave consequences of inadequate treatment, little is known about the impact of 
adherence to AD treatment on mortality in the general population. This study aimed 
to evaluate the association between adherence to AD and all-cause mortality in 
a population-based cohort. Methods: Data were extracted from the electronic 
medical database of the largest health provider in Israel, covering 53% of Israel’s 
population, and a total of 251,746 patients were included who had purchased AD 
at least once and were older than 40 years of age, between 2008-2011. Adherence 
was measured as mean possession ratio (duration of supplied AD divided by dura-
tion of prescribed AD) and was modeled as a four level variable: non-adherence 
(< 20%), poor (20%-50%), moderate (50% - 80%), and good (> 80%) adherence. We used 
survival analyses and included demographic and clinical variables to determine 
the adjusted association between AD adherence and mortality Results: The poor, 
moderate and good adherence groups had adjusted mortality hazard ratios of 0.93 
[95% Confidence interval (CI): 0.89 to 0.97], 0.83 [95% CI: 0.79 to 0.86] and 0.88 [95% 
CI: 0.85 to 0.91], respectively, with corresponding p-values < 0.0001 for all compari-
sons, compared to the non-adherent group. ConClusions: Adherence to AD, even 
at low levels, is associated with a corresponding decrease in the risk of mortality, 
controlling for relevant covariates. Physicians from all disciplines should actively 
improve their patients’ adherence to AD since their persistent use is associated 
with increased survival.
PMH5
findings of a retrosPeCtive study on faCtors resPonsible for 
dePression in india
Sachdeva M.1, Dhingra S.2, Parle M.3, Maharaj S.2
1Panjab University, Chandigarh, India, 2The University of the West Indies, St. Augustine, Trinidad 
and Tobago, 3Guru Jambheshwar University of Science and Technology, Hisar, India
objeCtives: Depression is a leading cause of morbidity and disability worldwide. 
The factors responsible for the prevalence of depression vary across countries 
and cultures. This study was aimed to provide data on the prevalence of depres-
sion and the possible risk factors responsible for its prevalence in Haryana State, 
India. Methods: A retrospective evaluation of the medical records was carried 
out at the psychiatric units of three different district government hospitals from 
September 2010 till August 2013. The data was analyzed by using the statistical 
software, SPSS version 13®. Results: The medical records of a total of 4512 patients 
with a confirmed diagnosis of depression were evaluated. The prevalence of depres-
sion was found to be significant among females (χ 2 = 32.9, df = 1, p< 0.001), as a 
majority (58 %) of the patients were females. In terms of ethnicity, seventy-eight 
percent patients were Hindus and mainly belonging to lower castes of community 
and other backward classes. However, in terms of age, majority, 1714 (38%) were 
over 50 years of age (χ 2 = 38.78, df = 1, p< 0.0001). Whilst evaluating the risk factors 
for depression, social problems and medical complications were the most common 
identified stressors during patient evaluation. Marital and family problems, followed 
by relationship/childhood problems and death of loved ones, were the frequent 
risk factors identified among females. However, financial and job related problems 
were the most common stressors identified among males. Among medical com-
plications, hypertension was most frequent ConClusions: Overall, the findings 
demonstrated a high rate of depression among people of low socioeconomic status 
and aged patients with medical complications.
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objeCtives: To describe the evolution and effect of prognostic factors on psychiatric 
hospitalization rates in schizophrenia patients over 3 years using the Cohort for 
the General study of Schizophrenia (CGS), a cohort established to provide a better 
understanding of schizophrenia outcomes and epidemiology in France. Methods: 
Between 2005-2011, 96 psychiatric centers recruited 1,388 patients meeting the 
following criteria: aged 15-65 years, DSM-IV criteria for schizophrenia, and treated 
as outpatients or hospitalized ≤ 3 months. Data on sociodemographics, body mass 
index (BMI), comorbidities, psychotropic treatments, disease severity as per Clinical 
Global Impression [CGI] scores, Brief Psychiatric Rating Scale, Global Assessment of 
Functioning scale, suicidality risk and suicide, were collected at baseline and semi-
annually. Crude psychiatric hospitalization rates per 100 person-years were calcu-
lated yearly and over 3 years of follow-up. Results: At cohort entry, mean age was 
38.7 years, 68.9% were men, average maximum CGI score was 5.8, and 46.1% were 
hospitalized in the past year. During follow-up, somatic comorbidities (cardiovas-
cular, endocrine, and respiratory) were stable at < 5%. Mean BMI was 25.3 at cohort 
entry and after 3 years. Hospitalization rates were: 53.8 (95% CI: 49.9-57.8) the first 
year, 54.8 (95% CI: 50.5-59.4) the second year, and 52.9 (95% CI: 48.5-57.6) the third 
year. By age group, 3-year hospitalization rates followed a bimodal distribution: 80.3 
among patients aged 15-24 years, 58.9 for patients aged 25-34 years, 45.1 for patients 
aged 35-44 years, 59.0 for patients aged 45-54 years, and 39.1 for patients ≥ 55 years. 
Rates were associated with higher baseline CGI scores (82.7 for a score of 7 [high-
est score]), appointed legal guardianship (69.4), and moderate or high suicide risk 
